RAAS: A Convergent Player in Ischemic Heart Failure and Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Jul 20

PMID 34281199

Citations 8

Authors

Texali C Garcia-Garduno

Jorge R Padilla-Gutierrez

Diego Cambron-Mora

Yeminia Valle

Affiliations

Soon will be listed here.

Abstract

The current global prevalence of heart failure is estimated at 64.34 million cases, and it is expected to increase in the coming years, especially in countries with a medium-low sociodemographic index where the prevalence of risk factors is increasing alarmingly. Heart failure is associated with many comorbidities and among them, cancer has stood out as a contributor of death in these patients. This connection points out new challenges both in the context of the pathophysiological mechanisms involved, as well as in the quality of life of affected individuals. A hallmark of heart failure is chronic activation of the renin-angiotensin-aldosterone system, especially marked by a systemic increase in levels of angiotensin-II, a peptide with pleiotropic activities. Drugs that target the renin-angiotensin-aldosterone system have shown promising results both in the prevention of secondary cardiovascular events in myocardial infarction and heart failure, including a lower risk of certain cancers in these patients, as well as in current cancer therapies; therefore, understanding the mechanisms involved in this complex relationship will provide tools for a better diagnosis and treatment and to improve the prognosis and quality of life of people suffering from these two deadly diseases.

Citing Articles

Anemia, Hyperglycemia, and Reduced Left Ventricular Ejection Fraction Improve the GRACE Score's Predictability for In-hospital Mortality in Acute Coronary Syndrome; Single-Centre Cross-Sectional Study.

Turu Allo I, Pramudyo M, Akbar M Open Access Emerg Med. 2025; 17:67-83.

PMID: 39927301 PMC: 11806914. DOI: 10.2147/OAEM.S493878.

The Complex Connection Between Myocardial Dysfunction and Cancer Beyond Cardiotoxicity: Shared Risk Factors and Common Molecular Pathways.

Molnar A, Birges K, Surman A, Merkely B Int J Mol Sci. 2024; 25(23).

PMID: 39684895 PMC: 11642109. DOI: 10.3390/ijms252313185.

Research progress of autophagy in heart failure.

Li L, Xi R, Gao B, Zeng Y, Ma Q, Gong T Am J Transl Res. 2024; 16(5):1991-2000.

PMID: 38883358 PMC: 11170578. DOI: 10.62347/OBXQ9477.

Genetic Variations Related to Angiotensin II Production and Risk for Basal Cell Carcinoma.

Gintoni I, Mastrogeorgiou M, Papakosta V, Vassiliou S, Yapijakis C Biochem Genet. 2024; .

PMID: 38546913 DOI: 10.1007/s10528-024-10746-0.

The severity of COVID-19 in hypertensive patients is associated with mirSNPs in the 3' UTR of that associate with miR-3658: In silico and in vitro studies.

Safdar M, Ozaslan M, Mustafa R, Smail S, Khan S, Khan M J Taibah Univ Med Sci. 2023; 18(5):1030-1047.

PMID: 36926053 PMC: 9981452. DOI: 10.1016/j.jtumed.2023.02.009.

References

Sim H, Zheng H, Richards A, Chen R, Sahlen A, Yeo K . Beta-blockers and renin-angiotensin system inhibitors in acute myocardial infarction managed with inhospital coronary revascularization. Sci Rep. 2020; 10(1):15184. PMC: 7495427. DOI: 10.1038/s41598-020-72232-y. View

Roger V . Epidemiology of heart failure. Circ Res. 2013; 113(6):646-59. PMC: 3806290. DOI: 10.1161/CIRCRESAHA.113.300268. View

Rudi W, Molitor M, Garlapati V, Finger S, Wild J, Munzel T . ACE Inhibition Modulates Myeloid Hematopoiesis after Acute Myocardial Infarction and Reduces Cardiac and Vascular Inflammation in Ischemic Heart Failure. Antioxidants (Basel). 2021; 10(3). PMC: 8001011. DOI: 10.3390/antiox10030396. View

Bissessor N, White H . Valsartan in the treatment of heart failure or left ventricular dysfunction after myocardial infarction. Vasc Health Risk Manag. 2007; 3(4):425-30. PMC: 2291334. View

Groenewegen A, Rutten F, Mosterd A, Hoes A . Epidemiology of heart failure. Eur J Heart Fail. 2020; 22(8):1342-1356. PMC: 7540043. DOI: 10.1002/ejhf.1858. View

Chappell M, Al Zayadneh E . Angiotensin-(1-7) and the Regulation of Anti-Fibrotic Signaling Pathways. J Cell Signal (Los Angel). 2017; 2(1). PMC: 5501273. DOI: 10.4172/2576-1471.1000134. View

Meijers W, Maglione M, Bakker S, Oberhuber R, Kieneker L, de Jong S . Heart Failure Stimulates Tumor Growth by Circulating Factors. Circulation. 2018; 138(7):678-691. DOI: 10.1161/CIRCULATIONAHA.117.030816. View

Selvaraj S, Bhatt D, Claggett B, Djousse L, Shah S, Chen J . Lack of Association Between Heart Failure and Incident Cancer. J Am Coll Cardiol. 2018; 71(14):1501-1510. DOI: 10.1016/j.jacc.2018.01.069. View

Regan D, Coy J, Chahal K, Chow L, Kurihara J, Guth A . The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment. J Immunol. 2019; 202(10):3087-3102. PMC: 6504574. DOI: 10.4049/jimmunol.1800619. View

10.

Silveira K, Coelho F, Vieira A, Sachs D, Barroso L, Costa V . Anti-inflammatory effects of the activation of the angiotensin-(1-7) receptor, MAS, in experimental models of arthritis. J Immunol. 2010; 185(9):5569-76. DOI: 10.4049/jimmunol.1000314. View

11.

Pugliese N, Masi S, Taddei S . The renin-angiotensin-aldosterone system: a crossroad from arterial hypertension to heart failure. Heart Fail Rev. 2019; 25(1):31-42. DOI: 10.1007/s10741-019-09855-5. View

12.

Konstam M, Neaton J, Dickstein K, Drexler H, Komajda M, Martinez F . Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial. Lancet. 2009; 374(9704):1840-8. DOI: 10.1016/S0140-6736(09)61913-9. View

13.

Brancaccio M, Pirozzi F, Hirsch E, Ghigo A . Mechanisms underlying the cross-talk between heart and cancer. J Physiol. 2019; 598(14):3015-3027. DOI: 10.1113/JP276746. View

14.

Ocaranza M, Riquelme J, Garcia L, Jalil J, Chiong M, Santos R . Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2019; 17(2):116-129. PMC: 7097090. DOI: 10.1038/s41569-019-0244-8. View

15.

. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875):821-8. View

16.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

17.

Emdin M, Fatini C, Mirizzi G, Poletti R, Borrelli C, Prontera C . Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible?. Clin Chim Acta. 2014; 443:85-93. DOI: 10.1016/j.cca.2014.10.031. View

18.

Mathieu S, El Khoury N, Rivard K, Paradis P, Nemer M, Fiset C . Angiotensin II Overstimulation Leads to an Increased Susceptibility to Dilated Cardiomyopathy and Higher Mortality in Female Mice. Sci Rep. 2018; 8(1):952. PMC: 5772611. DOI: 10.1038/s41598-018-19436-5. View

19.

Pfeffer M, Braunwald E, Moye L, Basta L, Brown Jr E, Cuddy T . Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992; 327(10):669-77. DOI: 10.1056/NEJM199209033271001. View

20.

Pinter M, Jain R . Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. Sci Transl Med. 2017; 9(410). PMC: 5928511. DOI: 10.1126/scitranslmed.aan5616. View